Actively Recruiting
Evaluation of Rilvegostomig Combined with Bevacizumab With or Without Tremelimumab Compared to Atezolizumab Plus Bevacizumab as First-Line Treatment for Advanced Hepatocellular Carcinoma
Led by AstraZeneca · Updated on 2026-10-13
1220
Participants Needed
226
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of rilvegostomig combined with bevacizumab, with or without tremelimumab, compared to atezolizumab combined with bevacizumab in people with advanced hepatocellular carcinoma HCC who cannot undergo curative or locoregional therapy. This Phase III, randomized, open-label, sponsor-blinded study includes a safety lead-in period before the main randomized treatment phase to assess tolerability. The study has three groups one receiving tremelimumab, rilvegostomig, and bevacizumab another receiving rilvegostomig and bevacizumab and a third group receiving atezolizumab and bevacizumab. All treatments are given by intravenous infusion. The initial safety lead-in is a single-arm phase focusing on the combination of rilvegostomig, bevacizumab, and tremelimumab, followed by a randomized period comparing the three treatment arms. Participants will be monitored for up to approximately six years to assess overall survival and other measures of treatment effect and safety. Assessments include evaluations of liver cancer progression, immune response, and any adverse events. The study involves regular clinical visits and evaluations to monitor health and treatment effects throughout the study duration.
CONDITIONS
Brief Title
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here